Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;29(7):285–289. doi: 10.1002/clc.4960290703

The physiologic basis for the management of ventricular assist devices

Gilbert H Mudge JR 1,, James C Fang 1, Colleen Smith 1, Gregory Couper 1
PMCID: PMC6654009  PMID: 16881535

Abstract

Mechanical ventricular assist devices are now approved as destination therapy for terminal heart failure. It is the purpose of this review to discuss the physiology of this technology that is considered in outpatient care. The currently available pulsatile devices are solely dependent of preload volume and, when placed in the automatic mode, can maintain physiologic cardiac outputs with exercise. However, because of their dependence on preload volume, there are unique physiologic consequences; device bradycardia represents volume depletion, device tachycardia reflects volume overload. The differential diagnosis of left ventricular assist device dysfunction includes native right ventricular failure, native left ventricular recovery, or other technical considerations. The management of biventricular mechanical support as well as arrhythmia management and the role of echocardiographic assessment in this unique patient population will be discussed. Expertise in outpatient management of such devices is now a requisite for subspecialists in heart failure. In the future, technical innovations may simplify management for professionals, patients, and their families.

Keywords: ventricular assist devices, destination therapy, left ventricular assist devices, right ventricular assist devices

Full Text

The Full Text of this article is available as a PDF (35.5 KB).

References

  • 1. Ogata K, Platt J: Potential applications and prospects for cardiac xenotransplantation. J Heart Lung Transplant 2004; 23: 515–526 [DOI] [PubMed] [Google Scholar]
  • 2. Oz MC, Geljins AC, Miller L, Wang C, Nickens P, Arons R, Aaronson K, Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson J, Rose EA, Moskowitz AJ: Left ventricular devices as permanent heart failure therapy: The price of progress. Ann Surg 2003; 238: 577–585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Portner PM, Jansen PGM, Oyer PE, Wheeldon DR, Ramasamy N: Im proved outcomes with an implantable ventricular assist system: A multicentered study. Ann Thorac Surg 2001; 71: 205–209 [DOI] [PubMed] [Google Scholar]
  • 4. DeRose JJ, Umana JP, Argenziano M, Catanese KA, Gardocki MT, Flannery MA, Sun BC, Rose EA, Oz MC: Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J Am Coll Cardiol 1997; 30: 1773–1777 [DOI] [PubMed] [Google Scholar]
  • 5. Rose EA, Gelijins AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meir P: Long‐term use of a left ventricular assist device for end‐stage heart failure. N Engl J Med 2001; 345: 1435–1443 [DOI] [PubMed] [Google Scholar]
  • 6. Digiorgi PL, Rao V, Naka Y, Oz MC: Which patient, which pump? J Heart Lung Transplant 2003; 22: 221–235 [DOI] [PubMed] [Google Scholar]
  • 7. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, McClellan D, Slepian MJ, for the Cardio West Total Artificial Heart Investigators : Cardiac replacement with a total artificial heart as a bridge to trans plantation. N Engl J Med 2004; 351: 859–867 [DOI] [PubMed] [Google Scholar]
  • 8. Horton SC, Khodaverdian R, Chatelian P, McIntosh ML, Horne BD, Muhlestein JB, Long JW: Left ventricular assist device malfunction: An approach to diagnosis by echocardiography. J Am Coll Cardiol 2005; 45: 1435–1440 [DOI] [PubMed] [Google Scholar]
  • 9. Horton SC, Khodaverdian R, Powers A, Revenaugh J, Renlund DG, Moore SA, Rasmisson B, Nelson KE, Long JW: Left ventricular assist device malfunction: A systematic approach to diagnosis. J Am Coll Cardiol 2004; 43: 1574–1584 [DOI] [PubMed] [Google Scholar]
  • 10. Birks EJ, Tansley PD, Yacoub MH, Bowles CT, Hipkin M, Hardy J, Banner NR, Khaghani A: Incidence and clinical management of life‐threatening left ventricular device failure. J Heart Lung Transplant 2004; 23: 964–969 [DOI] [PubMed] [Google Scholar]
  • 11. Helman DN, Maybaum SW, Morales DL, Williams MR, Beniaminovitz A, Edwards NM, Mancini DM, Oz MC: Recurrent remodeling after ventricular assistance: Is long term myocardial recovery attainable? Ann Thorac Surg 2000; 70: 1255–1258 [DOI] [PubMed] [Google Scholar]
  • 12. Hetzer R, Muller J, Weng Y, Wallukat G, Spiegelsberger S, Loebe M: Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 1999; 68: 742–749 [DOI] [PubMed] [Google Scholar]
  • 13. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB: Myocyte recovery after mechanical circulatory assist support in humans with end‐stage heart failure. Circulation 1998; 97: 2316–2322 [DOI] [PubMed] [Google Scholar]
  • 14. Jimmy KF, Yacoub MH: Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 2003; 75: S36–41 [DOI] [PubMed] [Google Scholar]
  • 15. Chen JM, Spanier TB, Gonzalez JJ, Marelli D, Flannery MA, Tector KA, Cullinane S, Oz MC: Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. J Heart Lung Transplant 1999; 18: 351–357 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES